I
t is well known that IL-2 exerts therapeutic activity in a fraction of patients with melanoma or renal cancer, with 5 and 9% complete response rates in metastatic patients receiving a high dose i.v. bolus (1, 2) . However, the majority of patients failed to respond to IL-2 therapy. The identification of a subset of regulatory T cells (Treg), 4 which coexpress CD4 and the IL-2R ␣-chain or CD25 and display potent immune-suppressive activity on T cell function (3) (4) (5) , suggested that IL-2 may have opposite effects, activating both effector functions and regulatory mechanisms. IL-2-mediated immune regulatory effects involve not only Treg, but also activation-induced cell death of effector cells (6) .
Indeed, CD25
Ϫ/Ϫ , CD122 (IL-2R␤) Ϫ/Ϫ , and IL-2 Ϫ/Ϫ mice show lymphoproliferation and develop autoimmune diseases (7) (8) (9) (10) , indicating that IL-2 has a primary role in immune regulation (11, 12) . Natural CD4 ؉ CD25 ؉ Tregs are a distinct lineage of T cells, expressing glucocorticoid-induced TNFR (GITR) (13, 14) , CTLA4 (15) , IL-10, TGF-␤ (5), and the transcription factor Forkhead/winged helix transcription factor (Foxp3) (16 -18) and physiologically control the immune system homeostasis, preventing autoimmune disorders (3, 4) . Several other lines of evidences indicate that not only naturally occurring, but also tumor-induced, Tregs, are involved in tumor-related immune suppression (5) . Thus, removal of CD4 ؉ CD25 ؉ cells by depleting Abs (19, 20) or interfering with their functions by CTLA4 blockade (21) or GITR signaling (22) may synergize with different immunotherapy strategies aimed at stimulating immune responses (23) .
IL-21, the last member of the IL-2 cytokine family and sharing functional overlaps with IL-2 and IL-15, may represent a new tool for tumor immunotherapy (24 -26) . Although IL-2 is required for tolerance, enhanced production of IL-21 has been implicated in the development of autoimmunity (27, 28) . The biological activities of IL-21 are mediated by a specific IL-21R (24, 29) , which associates with the common ␥-chain for signal transduction (30) and is independent from CD25 for its function. IL-21 induces activated NK cell terminal differentiation and functions, thereby limiting NK cell expansion by IL-15 (31) . In addition, IL-21 efficiently promotes proliferation, cytotoxic activity, and IFN-␥ production by murine and human CD8 ϩ effector T cells (32) . In view of these findings, it has been proposed that IL-21 drives the transition from NK cell responses to specific CTL responses (31) .
Previous studies in different murine models showed that IL-21 gene transfer in tumor cells induces tumor rejection, which depends predominantly on NK cells (33) and/or CTLs (34 -36) . In particular, we reported that TS/A tumor cells genetically modified to secrete IL-21 displayed a reduced tumorigenic potential in syngeneic mice and primed a protective immune response mediated by CD8
ϩ CTLs, IFN-␥, and IFN-␥-inducible CXC chemokines (35) .
In the present report we show that immunotherapy with irradiated TS/A cells genetically modified to secrete IL-21 (TS/A-IL-21) can inhibit the progression of TS/A-parental cell (pc) micrometastases, although only a fraction of mice are cured over the long term. The presence of CD4 ϩ CD25 ϩ T cells with strong immunesuppressive activity in tumors and draining lymph nodes (LN) suggested that IL-21 only partially overcomes Treg-related immune suppression. However, the effect of the IL-21-engineered cell vaccine was strongly potentiated by the coadministration of a Tregdepleting anti-CD25 mAb and led to the cure of most mice bearing TS/A-pc micrometastases.
Materials and Methods

Cell lines and IL-21-modified tumor cells
TS/A murine breast adenocarcinoma (37), C26 colon carcinoma, and F1F fibrosarcoma cells were cultured in DMEM supplemented with 2 mM Lglutamine, 1% PenStrep (Cambrex), and 10% FCS (Cambrex). The TS/A-IL-21 stable transfectant was previously described (35) . F1F cells were transfected with 10 g of pIL-21IRES1neo plasmid using the FuGene 6 reagent (Roche) and cloned (35) . IL-21 secretion was assessed by ELISA (R&D Systems) (33) .
TS/A-pc micrometastasis induction and immunotherapy
Five-to 7-wk-old female BALB/cAnNCrlBR (BALB/c) mice were purchased from Harlan Italy. IFN-␥ knockout mice (38) on a BALB/c background were obtained from The Jackson Laboratory. Homozygous mice were bred and maintained in isolators in-house. The animals were housed in a pathogen-free colony. Experiments were performed according to the National Regulation on Animal Research Resources and were approved by the institutional review board of the Istituto Nazionale per la Ricerca sul Cancro (Genova, Italy). Mice were inspected every day and were killed when they showed weight loss (Ͼ15%) or other signs of disease. The presence of metastases was autoptically confirmed.
Animals (five to seven mice per group) were injected i.v. with 5 ϫ 10 4 TS/A-pc/mouse for induction of micrometastases. Vaccination was performed on days 1, 3, 7, and 10 after micrometastasis induction (day 0) by s.c. injection of 1 ϫ 10 6 irradiated TS/A-IL-21, TS/A-pc, or F1F-IL-21. In vitro experiments showed that irradiated cells retained the ability to secrete IL-21 for at least 72 h. Cells were mycoplasma-free and were extensively washed in endotoxin-free medium before injection. Statistical analysis was performed by the log-rank or Mann-Whitney tests; a value of p Ͻ 0.05 was considered significant. Depletion studies were performed by i.p. injection of anti-CD8 (2.43) or anti-CD4 (GK1.5) rat mAbs, both from American Type Culture Collection, or of anti-asialo GM1 antiserum (Wako Chemicals) as previously reported (39) . CD25 ϩ cell depletion was performed by a single dose of 100 or 500 g of PC61 mAb (American Type Culture Collection) administered i.p. 24 h (or 48 in delayed-onset immunotherapy, as indicated) after micrometastasis induction, followed 6 h later by the first vaccination with irradiated TS/A-IL-21 cells. Control animals received irrelevant rat IgG.
Immunohistochemistry and two-color immunofluorescence
Groups of three BALB/c mice were killed 10 days after s.c. TS/A-pc inoculation or 17 days after induction of lung metastases.
For immunohistochemistry, acetone-fixed cryostat sections were immunostained with anti-CD4 (L3T4; clone YT5.191.1.2; Sera-lab) or anti-CD25 Ab (anti-IL-2Ra; clone 3C7; Santa Cruz Biotechnology). After washing, sections were overlaid with biotinylated goat anti-rat Ig (Vector Laboratories) for 30 min, washed, and incubated with avidin/biotin complex/alkaline phosphatase (DakoCytomation).
For double-immunofluorescent staining, acetone-fixed frozen sections were incubated for 30 min with the primary (rabbit) anti-CD3 (DakoCytomation) or anti-CD4 Ab and washed in PBS for 5 min. Next, sections were incubated for 30 min with biotinylated secondary Ab, washed, and incubated with AlexaFluor 488-conjugated streptavidin (Molecular Probes; 1/800) for 20 -30 min. After washing, sections were incubated for 30 min with the second PE-conjugated anti-CD25 Ab (anti-IL-2R␣; clone 3C7; Santa Cruz, Biotechnology) and then washed. Slides were examined with a Zeiss LSM 510 Meta laser scanning confocal microscope.
Identification and isolation of CD4
ϩ CD25 ϩ cells Ϫ cell fractions were isolated by a two-step immunomagnetic procedure (Miltenyi Biotec). Briefly, negative selection was performed with a mixture of biotin-conjugated anti-CD8, -CD11b, -CD45R, -CD49b, and -Ter-119 mAbs and anti-biotin Ab-conjugated magnetic beads, followed by a second step of positive selection by an anti-CD25-PE mAb and anti-PE Ab-conjugated microbeads. Purity was Ͼ90%, as assessed by immunofluorescence. 
Inhibition of T cell responses by Tregs
RT-PCR analysis of Foxp-3, GITR, IL-21R, and IL-10 expression
Total RNA was extracted from CD4 ؉ CD25 ؉ and CD4 ؉ CD25 Ϫ cell fractions using the RNeasy kit (Qiagen). RT-PCR was performed as previously described, using primers specific for the housekeeping gene ␤-actin (35) or for Foxp-3 (5Ј-CAG CTG CCT ACA GTG CCC CTA-3Ј and 5Ј-CAT TTG CCA GCA GTG GGT AG-3Ј), GITR (5Ј-TCT CGA TGC TCT GTG TGC TG-3Ј and CGT GGC ACA GGC AAC ACA C-3Ј), IL-21R (5Ј-CCAC CTCAAACCTTCACCTC and 5Ј-TGCTCTCAGCCAGGACAAAG), or IL-10 (5Ј-GCT ATG CTG CCT GCT CTT AC-3Ј and 5Ј-ACT CTT CAC CTG CTC CAC TG-3Ј) genes. The amplifications were conducted for 32 or 27 cycles (for ␤-actin).
In vitro restimulation and CTL assay
Spleen cells from cured mice (10 6 cells/ml) were restimulated in vitro for 5 days at 37°C in the presence of the gp70-derived L d -restricted AH1 peptide (40, 41) (SPSYVYHQF; Primm) at 1 g/ml. Cytolytic activity was evaluated by a standard 51 Cr release assay using F1F, C26, and TS/A-pc as target cells.
ELISPOT assay was performed on multiscreen Immobilon-P plates (Millipore) coated with anti-IFN-␥ Ab (Endogen). Splenocytes were seeded at 2 ϫ 10 5 /well in duplicate in the presence of relevant or irrelevant peptides. After 36 h, plates were washed and incubated with biotinylated second mAb to IFN-␥ (Endogen). Then, HRP-conjugated streptavidin (1/ 5000) was added for another 2 h. After washings, the plates were stained with a 3-amino-9-ethyl-carbazole kit (Sigma-Aldrich), and spots were counted using a stereomicroscope.
The evaluation of Treg inhibitory activity on AH1-induced IFN-␥ production was assessed by ELISPOT on spleen cells from naive or cured mice restimulated in vitro for 5 days with either AH1 peptide or an irrelevant peptide. Tumor draining LN CD4 ϩ CD25 ϩ Tregs were added at a 10:1 responder/Treg ratio in the presence or the absence of 60 ng/ml IL-21.
Results
IL-21 gene-modified tumor cells display therapeutic activity against TS/A-pc micrometastases
The therapeutic potential of TS/A-IL-21 cells was assessed in a micrometastatic TS/A-pc tumor model. Mice were injected i.v. on day 0 with 5 ϫ 10 4 viable TS/A-pc and were randomized into three groups: the first received no therapy, the second received four s.c. injections of 10 6 irradiated TS/A-IL-21 cells starting from day 1, and the third received the same schedule, but using irradiated TS/ A-pc as a control vaccine. Low, albeit detectable, levels of IL-21 (2.4 Ϯ 1 ng/ml) were present in the serum of mice 48 h after the last TS/A-IL-21 injection, whereas IL-21 was below the detection limit in the serum of mice receiving TS/A-pc. All mice receiving no therapy developed signs of metastases within 27 days and showed massive metastatic dissemination in their lungs at necropsy (Fig. 1, A and B) . Mice receiving immunotherapy with irradiated TS/A-IL-21 cells showed significantly increased tumorfree survival ( p Ͻ 0.0001) and a sharp reduction in the number of lung metastases, especially those showing a late (Ͼ35 days) onset of symptoms (Fig. 1B) . More importantly, 17% of TS/A-IL-21-treated mice achieved long-term survival (Ͼ150 days; Fig. 1A ) and were resistant to subsequent s.c. rechallenge with a fully tumorigenic dose of TS/A-pc. In the group of mice receiving irradiated TS/A-pc as therapy, only a slight increase in mean survival time was observed ( p ϭ NS), and no mouse showed a long-lasting cure (Fig. 1A) . Similarly, in a parallel experiment with a group of 10 mice, vaccination by TS/A cells transfected with the empty vector failed to cure any mice (data not shown).
Because the gp70env endogenous retroviral Ag is an immunodominant Ag of the TS/A tumor (40, 41), we analyzed whether mice cured by TS/A-IL-21 vaccine developed gp70-specific CTLs. Indeed, splenocytes from cured mice developed CTL activity against the gp70-expressing TS/A-pc and C26 carcinoma syngeneic cells upon restimulation in culture with the AH1 CTL epitope of gp70 (Fig. 1C) , whereas syngeneic F1F cells lacking gp70env were not lysed. The higher sensitivity of C26 to CTL-mediated lysis may be related to higher the MHC class I and gp70 expression levels in this cell line compared with TS/A-pc (40) . Unstimulated splenocytes from cured mice or AH1-stimulated splenocytes from naive mice failed to lyse TS/A-pc or C26 cells (data not shown). The induction of an Ag-specific immune response in cured mice was confirmed by ELISPOT assay. Splenocytes from cured mice showed higher numbers of IFN-␥-producing cells upon AH1 peptide stimulation compared with splenocytes from naive mice ( p Ͻ 0.01; Fig. 1D ).
These data indicated the induction of an Ag-specific immune response by TS/A-IL-21 vaccination. Indeed, if IL-21-transduced F1F (F1F-IL-21) cells were used as a vaccine, only an increase in the mean survival time was observed ( p Ͻ 0.03), but no animals were cured (Fig. 2B ). In addition, no induction of AH1-specific CTLs was observed in splenocytes from these mice (data not shown). Because F1F-IL-21 secreted ϳ2-fold more IL-21 than TS/ A-IL-21 ( Fig. 2A) , these data indicate that both the relevant Ag (gp70) and IL-21 should be expressed by the cell vaccine to induce a therapeutic effect.
cells with Treg activity are present in TS/A-pc tumors and draining lymph nodes
The limited therapeutic activity of TS/A-IL-21 vaccine prompted us to investigate whether CD4 ϩ CD25 ϩ Tregs play a role in this process. Indeed, CD25 ϩ cells were detected on frozen sections of TS/A-pc s.c. tumors (Fig. 3) or of lung metastases (Fig. 3g) by immunofluorescence or immunohistochemistry. At early stages, CD25 ϩ cells were found predominantly at the boundaries of tumor 6 TS/A-IL-21 s.c. on days 1, 3, 7, and 10 after challenge), and the third was given irradiated TS/A-pc, using the same doses and schedule described above. Data are expressed as tumor-free survival. TS/A-IL-21-vaccinated mice showed a statistically significant increase in survival rate (p Ͻ 0.0001 vs untreated; p Ͻ 0.04 vs TS/A-pc-vaccinated). B, Lungs from representative mice receiving no therapy or showing late (Ͼ35 days) or no signs of metastasis (Ͼ150 days survival). C, Cytolytic activity of splenocytes from mice cured by therapeutic vaccination performed after 6-day coculture with 1 g/ml of the AH1 epitope of gp70env. Data are expressed as the percent lysis of 51 Cr-labeled TS/A-pc, C26 or F1F cells in a 4-h assay. Lysis of target cells by splenocytes stimulated with no peptide or with an irrelevant peptide showed CTL activity Ͻ10% (not shown). D, IFN-␥ production assessed by an ELISPOT assay in the presence or the absence of AH1 gp70env epitope or with an irrelevant peptide. Splenocytes from naive mice (f) or from mice cured by immunotherapy (Ⅺ) were restimulated for 36 h in the presence of 1 g/ml of either peptide. Spots were counted using a stereomicroscope.
nodules, whereas at later stages they were found scattered throughout the tumor tissue. Two-color immunofluorescence analysis revealed that a substantial fraction of these CD25 ϩ cells were CD4 ϩ CD25 ϩ (Fig. 3, a-c) . In addition, most CD25 ϩ cells were CD3 ϩ (Fig. 3, e-g ). These data were confirmed by two-color immunofluorescence and FACS analysis of s.c. tumors and their draining LN cell suspensions (data not shown) demonstrating the existence of a CD4 ϩ CD25 ϩ population (6.5-12 and 7.5-9.6% of lymphoid cells in TS/A-pc tumors and draining LN, respectively, in six different experiments; Fig. 4, A and B) . In TS/A-pc tumors, variable proportions of CD25 ϩ cells coexpressed CD4 ϩ and predominantly had a CD25 low phenotype. In tumor draining LN, most CD25 ϩ cells were CD4 ϩ and CD25 bright . In addition, the majority (ϳ85%) of CD25 ϩ cells from draining LN coexpressed Foxp3 (Fig. 4, A  and B) , whereas in TIL, only a minor fraction (4.1-5.2% in four different experiments) coexpressed CD25 and Foxp3. Intriguingly, in TIL, a CD25 Ϫ Foxp-3 low population (4 -6.5%) was also found, whereas only 0.5% of draining LN cells had this phenotype (Fig.  4, A and B) .
We then isolated CD4 ϩ CD25 ϩ cells by immunomagnetic purification (Ͼ85% purity) from both tumor draining LN and TIL, although the latter with a lower yield. Consistent with the twocolor immunofluorescence data, Ͼ80 and ϳ60% of CD4 ϩ CD25 ϩ cells purified from draining LN or TIL, respectively, were Foxp3 ϩ and therefore represented bona fide Treg cells (Fig. 4, A and B) .
RT-PCR analyses showed that CD4 ϩ CD25 ϩ cells from TS/A-pc draining LN expressed GITR, Foxp3, and IL-10 mRNA, which appeared less expressed or undetectable in CD4 ϩ CD25 Ϫ cell fractions (Fig. 4C ). In addition, IL-21R mRNA was expressed on both CD25 ϩ and CD25 Ϫ CD4 ϩ cell subsets. Two-color immunofluorescence analysis revealed that only a minor fraction of CD25 ϩ cells coexpressed IL-21R, whereas most IL-21R ϩ cells were CD25 Ϫ (Fig. 4D ). CD4 ϩ CD25 ϩ cells from draining LN or TS/A-pc s.c. tumors strongly suppressed the proliferation of syngeneic lymphocytes in response to allogeneic stimulation with irradiated H2 b splenocytes (Fig. 5A) , whereas MLR proliferation was even increased by the addition of CD4 ϩ CD25 Ϫ LN cells under the same experimental conditions. Inhibition of MLR activity correlated with a potent suppression (Ͼ90%) of IL-2 secretion in the culture supernatant (data not shown), in keeping with the ability of Tregs to inhibit IL-2 gene expression (4), and addition of exogenous IL-2 (60 ng/ ml) restored proliferation (data not shown).
Titration experiments showed that tumor-associated or LN CD4 ϩ CD25 ϩ Tregs were potent suppressors able to inhibit MLR at a 16:1 or 32:1 responder cell/Treg ratio (Fig. 5B) . The addition 4 TS/A-pc, mice were randomized into three groups: the first was left untreated; the second was vaccinated with TS/A-IL-21, and the third was vaccinated with F1F-IL-21 cells, using the same doses and schedule as described in Fig. 1 . of rIL-21 at a final concentration of 10 ng/ml failed to reverse the inhibition mediated by CD4 ϩ CD25 ϩ cells in the MLR, whereas at 60 ng/ml, the proliferative response was partially restored. CD4 ϩ CD25 ϩ cells alone failed to proliferate in response to the allogeneic stimulus or anti-CD3 mAb in either the presence or the absence of IL-21 (Fig. 5, B and C) , suggesting that IL-21 was unable to support CD4 ϩ CD25 ϩ Treg proliferation, whereas IL-2 induced Treg cell proliferation (Fig. 5C) ϩ CD25 ϩ cells could be isolated only from TS/A-IL-21 draining LN and showed significant immune-suppressive activity in allogeneic MLR (data not shown).
We then tested the ability of CD4 ϩ CD25 ϩ Tregs isolated from TS/Apc draining LN to suppress IFN-␥ production in response to the AH1 peptide by T cells from naive mice or mice cured by TS/A-IL-21 vaccination. AH1 failed to induce IFN-␥ production by splenocytes from naive mice, even after secondary in vitro restimulation. In contrast, splenocytes from immune mice showed an increased number of IFN-␥-secreting cells, which were significantly decreased when CD4 ϩ CD25 ϩ cells were present in the system (at a 10:1 responder cell/Treg ratio). IL-21 did not restore the IFN-␥ response. These findings indicate that draining LN CD4 ϩ CD25 ϩ cells may inhibit gp70 Ag-specific memory responses.
In vivo depletion of CD25 ϩ cells augmented the effect of TS/A-IL-21 cell vaccination
Because of the high activity of Tregs in TS/A-pc tumor-bearing mice, we tested whether CD25 ϩ cell depletion combined with TS/ A-IL-21 cellular vaccine could cooperate to cure micrometastases that had been induced 24 h before starting any treatment. Because IL-21R is expressed on CD25 Ϫ lymphocytes (Fig. 4D ) and functions independently from IL-2R␣ (CD25), it is conceivable that IL-21 may stimulate immune responses in CD25-depleted mice. As shown in Fig. 6A , a single dose of 500 g of anti-CD25 depleting Ab (42) given 1 day after TS/A-pc cells almost completely depleted CD25 ϩ cells in draining LN from TS/A-pc tumor-bearing hosts collected 10 days after Ab administration. In addition, Foxp3 ϩ cells were significantly depleted by anti-CD25 mAb treatment (from 6.6 to 0.7%) in draining LN (Fig. 6B) . Time-course experiments showed that Tregs were restored in LN only ϳ50 days after Ab treatment (data not shown). Despite this effect, the sole anti-CD25 Ab, administered 24 h after micrometastasis induction, had no effect on the mean survival time of mice (Fig. 6C) . However, if anti-CD25 mAb administration was followed 6 h later (30 h after micrometastasis induction) by TS/A-IL-21 vaccination, most (Ͼ80%) mice showed complete cure and long-term survival ( p Ͻ 0.0001 vs untreated; p Ͻ 0.002 vs TS/A-IL-21-treated), indicating a strong cooperative effect of CD25 ϩ Treg depletion and the IL-21-based cellular vaccine. All cured mice (nine of nine) showed resistance to another s.c. rechallenge with TS/A-pc performed 100 days after metastasis induction, suggesting that the effective immunotherapy was followed by a long-lasting protective immunity. The effect of the anti-CD25 mAb was dose related, because a single dose of 100 g of anti-CD25 mAb combined with TS/A-IL-21 vaccination cured only 28% (two of seven) of the mice (data not shown).
The combined immunotherapy was also effective if the anti-CD25 mAb was administered 48 h after micrometastasis induction, and the first vaccine dose was given 6 h later. In this delayed-onset immunotherapy setting, a significant increase in mean survival time was observed, and 71% of mice had long-lasting cure (Fig. 6D) .
The effect of anti-CD25 Ab and TS/A-IL-21 vaccination requires CD8 ϩ T cells, NK cells, and IFN-␥
Mice cured by the combined anti-CD25 mAb and TS/A-IL-21 vaccine showed gp70-specific CTL responses and IFN-␥ production in response to AH1 peptide stimulation (data not shown). We then studied the roles of CD8 and CD4-positive T cell subsets using anti-CD4 or anti-CD8 depleting Abs. As shown in Fig. 7A , CD4 ϩ T cell depletion failed to inhibit the effect of the combined anti-CD25 mAb and TS/A-IL-21 therapy, because 100% of CD4-depleted mice showed long-term survival. By contrast, all mice depleted of CD8 ϩ cells developed tumors; however, their mean survival time was longer than that of untreated mice, suggesting the involvement not only of CTLs, but also of other cell types (Fig.  7A) . Indeed, NK cell depletion by treatment with anti-asialo-GM1 antiserum reduced the number of cured mice to 14% (Fig. 7A) .
The role of IFN-␥ was also studied in syngeneic IFN-␥ Ϫ/Ϫ mice, where TS/A-pc tumor draining LN also showed a CD4 ϩ CD25 ϩ population accounting for ϳ8% of lymphoid cells (data not shown). As shown in Fig. 7B, no IFN 
Discussion
In this study we show that immunotherapy with irradiated IL-21-transduced TS/A mammary adenocarcinoma cells produces longterm cures in ϳ20% of syngeneic mice bearing wild-type tumor micrometastases. The therapeutic activity required a vaccine coexpressing the relevant tumor-associated Ags and IL-21, because the use of antigenically unrelated IL-21-secreting cells or nontransduced TS/A-pc failed to cure any mice.
We hypothesized that the poor therapeutic effect of the TS/A-IL-21 cellular vaccine might be related to immune regulatory mechanisms activated by the tumor. In this context, Tregs have been reported to expand in neoplasms and may therefore contribute to tumor-related immune regulation (43) (44) (45) . Our present data indicate that CD4 ϩ CD25 ϩ T cells were present in TS/A-pc tumors and tumor draining LN and were endowed with potent immunesuppressive properties. Our findings indicate that most CD4 ϩ CD25 ϩ cells isolated from the TS/A-pc tumor draining LN displayed several features of naturally arising Tregs (46): they were CD25 bright , they expressed Foxp3, and they also displayed GITR, IL-10, and TGF-␤ mRNA (Fig. 4 and data not shown) .
It has been proposed that TGF-␤ can induce the differentiation of CD4 ϩ CD25 Ϫ precursors into functional CD4 ϩ CD25 ϩ Tregs through the induction of Foxp3 (47 Ϫ cells have recently been shown to constitute a peripheral reservoir of Tregcommitted cells, which can be recruited to the CD25 ϩ pool upon activation stimuli (49) . Thus, it also plausible that such cells may be recruited at the TS/A-pc tumor site and then differentiate in the tumor microenvironment into CD25
ϩ Foxp3 ϩ cells.
By in vitro assays we showed that IL-21 could partially revert the immune-suppressive activity of CD4 ϩ CD25 ϩ Tregs from tumor draining LN only at a high concentration, which is unlikely to be reached using IL-21-engineered cells. This high dose effect could be related to the known direct effect of IL-21 on CTL activation and proliferation (24, 31, 32) , rather than to Treg inhibition. Moreover, small s.c. tumor nodules induced by TS/A-IL-21 cells and the related tumor draining LN also showed the presence of CD25 ϩ CD4 ϩ cells, which were endowed with immune-suppressive properties (data not shown), suggesting that low dose IL-21 is unable to suppress Treg function in vitro or in vivo. Because we were unable to select TS/A transfectants secreting greater amounts of IL-21, the possibility that high doses of IL-21 might override Treg inhibition in the TS/A-pc micrometastasis model remains to be determined. However, the administration of a single dose of anti-CD25 depleting mAb a few hours before TS/A-IL-21 immunotherapy strongly potentiated the therapeutic effect, leading to a Ͼ70% cure rate and long-term immunity to TS/A-pc Ags. This finding appears to constitute an authentic synergistic rather than a merely additive effect, because the administration of anti-CD25 mAb alone had no effect on mouse survival. This finding is consistent with previous reports showing that the administration of anti-CD25 Ab after tumor challenge is usually poorly effective (19, 20) . Although CD25 ϩ cell depletion is not selective for Tregs, this treatment strongly reduced the number of Foxp3 ϩ cells in tumor draining LN, suggesting that the cooperative effects achieved with the IL-21-secreting cellular vaccine may be related to Treg depletion. Because the biological activity of IL-2 requires cell surface expression of CD25 for high affinity binding, this cytokine cannot conveniently be combined with anti-CD25 mAbs; the CD25-independent IL-2-like immune-stimulating activities of IL-21, in contrast, offer a rationale for combining IL-21-based cellular vaccines with anti-CD25 mAbs. The finding that IL-21R is expressed on CD25 Ϫ lymphoid cells underscores the feasibility of this approach. In addition, although IL-2 has a role in tolerance (11, 12) , IL-21 has been implicated in the development of autoimmune disorders (26, 27) and may thus overcome tolerance constraints, suggesting that IL-21 may represent a more suitable adjuvant for cancer vaccines than IL-2.
The finding that CD4 ϩ CD25 ϩ Tregs from tumor draining LN fail to proliferate in response to IL-21 and alloantigen or anti-CD3 stimulation could imply that IL-21 is not directly involved in the control of Treg proliferation, although some of these cells may express the IL-21R gene. This offers a possible advantage compared with the use of IL-2, which is capable of supporting Treg proliferation. Moreover, our present data confirm that TS/A-IL-21 cells induce gp70 Ag-specific CTL responses (35) , which become more effective in mice depleted of Tregs. Several previous reports indicate that IL-21 is a suitable adjuvant for the induction of CTL responses, and that NK cells, too, may participate in the IL-21-mediated antitumor effects (34 -36) . Indeed, both CTLs and NK cells were involved in immunotherapy combining the antiCD25mAb and the TS/A-IL-21 vaccine. Other reports showed that CD4 ϩ lymphocytes play a role in antitumor immune responses in mice predepleted of CD25 ϩ cells (50, 51) , whereas CD4 ϩ T cells were not needed in the IL-21-based immunotherapy described in this study. It is possible that IL-21, which is a helper-derived factor (24) , by-passes the requirement for other factors released by CD4 ϩ Th cells. Finally, IFN-␥ was also necessary for the immunotherapy combining TS/A-IL-21 and anti-CD25 mAb, because syngeneic IFN-␥ Ϫ/Ϫ mice bearing TS/A-pc micrometastases could not be cured by this treatment.
In conclusion, our data indicate that the therapeutic activity of a low dose secreting IL-21-based cellular vaccine can be greatly potentiated by a single dose of a depleting anti-CD25 mAb, thereby allowing a strong antitumor effect and the induction of long-term protective immunity.
